MedTrace Logo

Phase II Proof of Concept Study in Uncomplicated UTI

NCT03129295 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-04-26

No results posted yet for this study

Summary

A study of the efficacy and safety of MPC-SHRC for the relief of symptoms associated with uncomplicated urinary tract infections.

Conditions

Interventions

DRUG

MPC-SHRC

Oral tablet four times a day for 3 days

DRUG

Placebo Oral Tablet

Oral tablet four times a day for 3 days

Sponsors & Collaborators

  • Mission Pharmacal

    lead INDUSTRY

Principal Investigators

  • Margaret E. Hurley, MD · Hurley Consulting Associates Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-30
Primary Completion
2017-09-30
Completion
2017-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129295 on ClinicalTrials.gov